Disease · MONDO_0006624

overactive bladder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. overactive bladder. Diseases, record MONDO_0006624. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006624

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: overactive bladder; Open Targets
Open Targets ID: MONDO_0006624; Open Targets
Other names: Hypertonic bladder, OAB, Overactive Detrusor, Urgent micturition, Urinary Bladder Overactive, Urinary urgency, overactive bladder (disease); Open Targets
Disease Ontology: DOID:0070355; Disease Ontology
MeSH: D053201; MeSH
Highest stage of its drugs: Approval, for 18 of its 75 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs75

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MIRABEGRON	CHEMBL2095212	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	76	70	70	Drugs and targets
SOLIFENACIN	CHEMBL1734	Small molecule	Approval	TTD	43	42	42	Drugs and targets
TOLTERODINE	CHEMBL1382	Small molecule	Approval	TTD	42	41	41	Drugs and targets
SOLIFENACIN SUCCINATE	CHEMBL1200803	Small molecule	Approval	DailyMed and PMDA	44	34	34	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Approval	DailyMed	32	31	16	Drugs and targets
FESOTERODINE	CHEMBL1201764	Small molecule	Approval	EMA Human Drugs	30	29	29	Drugs and targets
OXYBUTYNIN	CHEMBL1231	Small molecule	Approval	DailyMed	30	23	23	Drugs and targets
DARIFENACIN	CHEMBL1346	Small molecule	Approval	TTD	12	11	11	Drugs and targets
VIBEGRON	CHEMBL2107826	Small molecule	Approval	DailyMed, EMA Human Drugs, FDA, PMDA and TTD	15	9	9	Drugs and targets
TROSPIUM CHLORIDE	CHEMBL3084748	Small molecule	Approval	DailyMed	19	8	8	Drugs and targets

1 to 10 of 75

See all 75 drugs

Targets71

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CHRM3	Muscarinic acetylcholine receptor	16	Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor antagonist	Approval	https://conductscience.org/library/genes/1131	Drugs and targets
CHRM2	Muscarinic acetylcholine receptor	14	Muscarinic acetylcholine receptor M2 antagonist; Muscarinic acetylcholine receptor antagonist	Approval	https://conductscience.org/library/genes/1129	Drugs and targets
ADRB3	Beta-3 adrenergic receptor	4	Beta-3 adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/155	Drugs and targets
SNAP25	Synaptosomal-associated protein 25	4	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Approval	https://conductscience.org/library/genes/6616	Drugs and targets
TRPV1	Transient receptor potential cation channel subfamily V member 1	4	Vanilloid receptor antagonist; Vanilloid receptor inhibitor; Vanilloid receptor opener	Phase 2	https://conductscience.org/library/genes/7442	Drugs and targets
ESR1	Estrogen receptor	3	Estrogen receptor alpha agonist; Estrogen receptor modulator	Phase 2/3	https://conductscience.org/library/genes/2099	Drugs and targets
PDE5A	cGMP-specific 3',5'-cyclic phosphodiesterase	3	Phosphodiesterase 5A inhibitor	Phase 2	https://conductscience.org/library/genes/8654	Drugs and targets
TACR1	Substance-P receptor	3	Neurokinin 1 receptor antagonist	Phase 2	https://conductscience.org/library/genes/6869	Drugs and targets
CACNA1A	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/773	Drugs and targets
CACNA1B	Voltage-gated calcium channel	2	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/774	Drugs and targets

1 to 10 of 71

See all 71 targets

Trials303

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 18 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01488578	Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)		11,157	2012-06-14	Overactive Bladder	TOLTERODINE TARTRATE	Its record names the disease	ClinicalTrials.gov
NCT01972841	This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder	Phase 3	3,527	2018-06-12	Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence	MIRABEGRON, SOLIFENACIN SUCCINATE	Its record names the disease	ClinicalTrials.gov
NCT00688688	Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder	Phase 3	2,792	2012-10-19	Urinary Bladder, Overactive	MIRABEGRON, TOLTERODINE	Its record names the disease	ClinicalTrials.gov
NCT01936870	Drug Use Investigation for Toviaz		2,521	2017-04-07	Overactive Bladder (OAB)	FESOTERODINE	Its record names the disease	ClinicalTrials.gov
NCT00611026	Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.	Phase 3	2,417	2011-01-12	Overactive Bladder	FESOTERODINE, TOLTERODINE	Its record names the disease	ClinicalTrials.gov
NCT00689104	Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder	Phase 3	2,336	2012-10-17	Urinary Bladder, Overactive	MIRABEGRON, TOLTERODINE	Its record names the disease	ClinicalTrials.gov
NCT01908829	A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)	Phase 3	2,174	2017-10-09	Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases	MIRABEGRON	Its record names the disease	ClinicalTrials.gov
NCT00662909	A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder	Phase 3	2,149	2012-10-17	Urinary Bladder, Overactive	MIRABEGRON	Its record names the disease	ClinicalTrials.gov
NCT00912964	A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder	Phase 3	2,030	2012-10-17	Urinary Bladder, Overactive	MIRABEGRON	Its record names the disease	ClinicalTrials.gov
NCT01302067	A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine	Phase 4	2,012	2013-12-24	Overactive Bladder	FESOTERODINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 303

See all 303 trials

Comparisons in its trials80

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Male vs Female: Risk Factors for the Proportion of Responders of Tolterodine-Gender	2,745 of 3,394	3,791 of 4,386	7,780	NCT01488578	Trial comparisons
With Non-drug Therapies vs Without Non-drug Therapies: Risk Factors for the Proportion of Responders of Tolterodine-Non-drug Therapies	317 of 360	6,219 of 7,420	7,780	NCT01488578	Trial comparisons
With Concomitant Drugs vs Without Concomitant Drugs: Risk Factors for the Proportion of Responders of Tolterodine-Concomitant Drugs	3,483 of 4,214	3,053 of 3,566	7,780	NCT01488578	Trial comparisons
With Complications vs Without Complications: Risk Factors for the Proportion of Responders of Tolterodine-Complications	3,960 of 4,806	2,576 of 2,974	7,780	NCT01488578	Trial comparisons
<65 Years vs >=65 Years: Risk Factors for the Proportion of Responders of Tolterodine-Age	2,060 of 2,379	4,476 of 5,401	7,780	NCT01488578	Trial comparisons
With Previous Treatment vs Without Previous Treatment: Risk Factors for the Proportion of Responders of Tolterodine-Previous Treatment	698 of 943	5,753 of 6,736	7,679	NCT01488578	Trial comparisons
With Urinary Urgency vs Without Urinary Urgency: Risk Factors for the Proportion of Responders of Tolterodine-Urinary Urgency	5,529 of 6,521	829 of 1,043	7,564	NCT01488578	Trial comparisons
With BPH vs Without BPH: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Tolterodine - Comorbidity of Prostatic Hypertrophy	319 of 2,203	130 of 1,855	4,058	NCT01488578	Trial comparisons
Mirabegron 50 mg vs Solifenacin 5 mg: serious adverse events	14 of 936	13 of 934	1,870	NCT01638000	Trial comparisons
Vibegron 75 Milligrams (mg) Once Daily (QD) vs Placebo: deaths from any cause	0 of 553	0 of 551	1,104	NCT03902080	Trial comparisons

1 to 10 of 80

See all 80 comparisons in its trials

Papers from its trials172

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31961829	RESULT	1	PubMed
30661513	RESULT	1	PubMed
30266334	RESULT	1	PubMed
29556972	RESULT	1	PubMed
29398096	RESULT	1	PubMed
29140559	RESULT	1	PubMed
28714288	RESULT	1	PubMed
28102552	RESULT	1	PubMed
27648660	RESULT	1	PubMed
27092789	RESULT	1	PubMed

1 to 10 of 172

See all 172 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006624

GET https://conductscience.org/api/diseases/v1/MONDO_0006624/drugs?page=2

API reference For AI assistants